BIOMAT Database Logo BIOMAT Database Logo

Phase I/II trial of multicycle high-dose chemotherapy with peripheral blood stem cell support for treatment of advanced ovarian cancer. 2006

N Frickhofen, and W E Berdel, and F Opri, and R Haas, and A Schneeweiss, and M Sandherr, and W Kuhn, and D K Hossfeld, and C Thomssen, and H Heimpel, and R Kreienberg, and A Hinke, and V Möbus, and , and
Department of Hematology/Oncology, Universitätsklinikum Ulm, Ulm, Germany. norbert.frickhofen@hsk-wiesbaden.de

Ovarian cancer is chemosensitive, but most patients with advanced disease die from tumor progression. As 25% of the patients can be cured by chemotherapy, it is reasonable to evaluate high-dose chemotherapy (HDCT). Forty-eight patients with untreated ovarian cancer were entered in a multicenter phase I/II trial of multicycle HDCT. Median age was 46 (19-59 years); International Federation of Gynecology and Obstetrics-stage was III in 79% and IV in 21%; 31% had residual disease >1 cm after surgery. Two courses of induction/mobilization therapy with cyclophosphamide (250 mg/m2) and paclitaxel (250 mg/m2) were used to collect peripheral blood stem cells. HDCT consisted of two courses of carboplatin (area under curve (AUC) 18-22) and paclitaxel followed by one course of carboplatin and melphalan (140 mg/m2) with or without etoposide (1600 mg/m2). Main toxicity was gastrointestinal. Limiting carboplatin to AUC 20 and eliminating etoposide resulted in manageable toxicity (69% without grade 3/4 toxicity). One patient died from treatment-related pneumonitis. At 8 years median follow-up, median progression-free-survival (PFS) and overall survival (OS) is 13.3 and 37.0 months. Five-years PFS and OS is 18 and 33%. Multicycle HDCT is feasible in a multicenter setting. A European phase III trial based on this regimen is evaluating the efficacy of HDCT.

UI MeSH Term Description Entries
D008558 Melphalan An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen. Medphalan,Merphalan,Phenylalanine Mustard,Sarcolysine,Sarkolysin,4-(Bis(2-chloroethyl)amino)phenylalanine,Alkeran,L-PAM,Mustard, Phenylalanine
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D016190 Carboplatin An organoplatinum compound that possesses antineoplastic activity. cis-Diammine(cyclobutanedicarboxylato)platinum II,Blastocarb,CBDCA,Carboplat,Carbosin,Carbotec,Ercar,JM-8,NSC-241240,Nealorin,Neocarbo,Paraplatin,Paraplatine,Platinwas,Ribocarbo,JM 8,JM8,NSC 241240,NSC241240

Related Publications

N Frickhofen, and W E Berdel, and F Opri, and R Haas, and A Schneeweiss, and M Sandherr, and W Kuhn, and D K Hossfeld, and C Thomssen, and H Heimpel, and R Kreienberg, and A Hinke, and V Möbus, and , and
Rationale for very high-dose chemotherapy with peripheral blood stem cell support in advanced ovarian cancer.
January 1990, Haematologica,
N Frickhofen, and W E Berdel, and F Opri, and R Haas, and A Schneeweiss, and M Sandherr, and W Kuhn, and D K Hossfeld, and C Thomssen, and H Heimpel, and R Kreienberg, and A Hinke, and V Möbus, and , and
Phase II study of "dose-dense" high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer.
May 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
N Frickhofen, and W E Berdel, and F Opri, and R Haas, and A Schneeweiss, and M Sandherr, and W Kuhn, and D K Hossfeld, and C Thomssen, and H Heimpel, and R Kreienberg, and A Hinke, and V Möbus, and , and
High-dose chemotherapy with autologous peripheral stem cell support in advanced ovarian cancer.
February 1995, Annals of medicine,
N Frickhofen, and W E Berdel, and F Opri, and R Haas, and A Schneeweiss, and M Sandherr, and W Kuhn, and D K Hossfeld, and C Thomssen, and H Heimpel, and R Kreienberg, and A Hinke, and V Möbus, and , and
Very high-dose chemotherapy with autologous peripheral stem cell support in advanced ovarian cancer.
November 1995, European journal of cancer (Oxford, England : 1990),
N Frickhofen, and W E Berdel, and F Opri, and R Haas, and A Schneeweiss, and M Sandherr, and W Kuhn, and D K Hossfeld, and C Thomssen, and H Heimpel, and R Kreienberg, and A Hinke, and V Möbus, and , and
High-dose chemotherapy with peripheral blood stem cell transplantation for patients with advanced ovarian cancer.
April 2001, Journal of cancer research and clinical oncology,
N Frickhofen, and W E Berdel, and F Opri, and R Haas, and A Schneeweiss, and M Sandherr, and W Kuhn, and D K Hossfeld, and C Thomssen, and H Heimpel, and R Kreienberg, and A Hinke, and V Möbus, and , and
High-dose chemotherapy with autologous stem cell support in advanced ovarian cancer.
April 1996, Annals of medicine,
N Frickhofen, and W E Berdel, and F Opri, and R Haas, and A Schneeweiss, and M Sandherr, and W Kuhn, and D K Hossfeld, and C Thomssen, and H Heimpel, and R Kreienberg, and A Hinke, and V Möbus, and , and
Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT.
September 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
N Frickhofen, and W E Berdel, and F Opri, and R Haas, and A Schneeweiss, and M Sandherr, and W Kuhn, and D K Hossfeld, and C Thomssen, and H Heimpel, and R Kreienberg, and A Hinke, and V Möbus, and , and
Phase I/II study of tandem high-dose chemotherapy with autologous peripheral blood stem cell transplantation for advanced multiple myeloma.
December 2009, International journal of hematology,
N Frickhofen, and W E Berdel, and F Opri, and R Haas, and A Schneeweiss, and M Sandherr, and W Kuhn, and D K Hossfeld, and C Thomssen, and H Heimpel, and R Kreienberg, and A Hinke, and V Möbus, and , and
High-dose chemotherapy with peripheral blood stem cell transplantation for advanced testicular cancer.
March 2002, International journal of urology : official journal of the Japanese Urological Association,
N Frickhofen, and W E Berdel, and F Opri, and R Haas, and A Schneeweiss, and M Sandherr, and W Kuhn, and D K Hossfeld, and C Thomssen, and H Heimpel, and R Kreienberg, and A Hinke, and V Möbus, and , and
High-dose chemotherapy with peripheral blood stem cell transplantation for advanced testicular cancer.
July 2000, International journal of urology : official journal of the Japanese Urological Association,
Copied contents to your clipboard!